Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10009 of 10159  at  6/18/2019 3:02:43 PM  by

evernewbliss


 In response to msg 10007 by  Aspector
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

I think ANG3 and PCSK9 will address different segments of the market. PCSK9 will be preferred where you need to only lower LDL. ANG3 will be preferred where there is need to lower both LDL and TG. Negative of ANG3 is that it doesn’t only reduce LDL, but it also reduces HDL by the same percentage. So the ration between LDL/HDL doesn’t change. It would take Head to Head outcome trial between PCSK9 and ANG3 to convince physicians that lowering of HDL is not an issue.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 286
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...